Synthesis of (4-[18F]fluorophenyl)triphenylphosphonium as a potential imaging agent for mitochondrial dysfunction

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 48, Issue 2, 2005, Pages 131-137

  Cheng, Zhen ^a   Subbarayan, Murugesan ^a   Chen, Xiaoyuan ^a   Gambhir, Sanjiv Sam ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

F 18; Imaging; Mitochondria; Phosphonium

Indexed keywords

FLUORINE COMPOUNDS; MOLECULAR IMAGING;

F-18; IMAGING AGENT; IN-VIVO; MITOCHONDRIAL DISEASE; MITOCHONDRIAL DYSFUNCTION; MITOCHONDRIAS; MOLECULAR PROBES; PET RADIOLIGAND; PHOSPHONIA; POTENTIAL IMAGING;

MITOCHONDRIA;

(4 FLUOROPHENYL)TRIPHENYLPHOSPHONIUM F 18; 4 NITROPHENYLTRIPHENYLPHOSPHONIUM; FLUORINE 18; RADIOLIGAND; TETRAPHENYLPHOSPHONIUM; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG PURIFICATION; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; ISOTOPE LABELING;

EID: 14644435826     PISSN: 03624803     EISSN: None     Source Type: Journal    
DOI: 10.1002/jlcr.906     Document Type: Article

References (26)

1. Szewczyk A, Wojtczak L. Pharmacol Rev 2002; 54: 101-127.
2. Wallace DC. Science 1999; 283: 1482-1488.
3. Costantini P, Jacotot E, Decaudin D, Kroemer G. J Natl Cancer Inst 2000; 92: 1042-1053.
4. Hockenbery DM, Giedt CD, O'Neill JW, Manion MK, Banker DE. Adv Cancer Res 2002; 85: 203-242.
5. Modica-Napolitano JS, Aprille JR. Cancer Res 1987; 47: 4361-4365.
6. Kroemer G. Biochem Biophys Res Commun 2003; 304: 433-435.
7. Murphy MP. Trends Biotechnol 1997; 15: 326-330.
8. Murphy MP, Smith RAJ. Adv Drug Deliv Rev 2000; 41: 235-250.
9. Weissig V, Cheng S-M, Gerard D'Souza GM. Mitochondrion 2004; 3: 229-244.
10. Weissig V. Crit Rev Ther Drug Carrier Syst 2003; 20: 1-62.
11. Smith RA, Porteous CM, Gane AM, Murphy MP. Proc Natl Acad Sci USA 2003; 100: 5407-5412.
12. Modica-Napolitano JS, Aprille JR. Cancer Res 1987; 47: 4361-4365.
13. Modica-Napolitano JS, Aprille JR. Adv Drug Deliv Rev 2001; 49: 63-70.
14. Rideout DC, Calogeropoulou T, Jaworski JS, Dagnino Jr R, McCarthy MR. Anti-Cancer Drug Des 1989; 4: 265-280.
15. Rideout D, Bustamante A, Patel J. Int J Cancer 1994; 57: 247-253.
16. Modica-Napolitano JS, Koya K, Weisberg E, Brunelli BT, Li Y, Chen LB. Cancer Res 1996; 56: 544-550.
17. Britten CD, Rowinsky EK, Baker SD, Weiss GR, Smith L, Stephenson J, Rothenberg M, Smetzer L, Cramer J, Collins W, Von Hoff DD, Eckhardt SG. Clin Cancer Res 2000; 6: 42-49.
18. Ross GF, Smith PM, McGregor A, Turnbull DM, Lightowlers RN. Bioconjugate Chem 2003; 14: 962-966.
19. Steichen JD, Weiss MJ, Elmaleh DR, Martuza RL. J Neurosurg 1991; 74: 116-122.
20. Madar I, Weiss L, Izbicki G. J Nucl Med 2002; 43: 234-238.
21. Min JJ, Biswal S, Deroose C, Gambhir SS. J Nucl Med 2004; 45: 636-643.
22. Madar I, Anderson JH, Szabo Z, Scheffel U, Kao P-F, Ravert HT, Dannals RF. J Nucl Med 1999; 40: 1180-1185.
23. Madar I, Nelkin B, Isaacs JT, Ravert HT, Scheffel U, Dannals RF, Frost JJ. J Nucl Med 2003; 44: 179P-180P.
24. Ravert HT, Madar I, Dannals RF. J Label Compd Radiopharm 2004; 47: 469-476.
25. Rieke RD, White CK, Milliren CM. J Am Chem Soc 1976; 98: 6872-6877.
26. Lambert C, Gaschler W, Noll G, Weber M, Schmalzlin E, Brauchle C, Meerholz Klaus. J Chem Soc Perkin Trans 2 2001; 6: 964-974.